Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380803 | 0.84 | ALDH1A1 (0.68) | ALDH1A1ABCB11NR3C1CYP1A2CYP3A4 | |
| SCHEMBL1971208 | 0.81 | IMPDH2 (0.44) | ALDH1A1CYP3A4IMPDH2IMPDH1AR | |
| SCHEMBL12456472 | 0.77 | APLNR (0.42) | ALDH1A1ABCB11NR3C1CYP1A2CYP3A4 | |
| SCHEMBL151936 | 0.77 | IMPDH2 (0.64) | ALDH1A1IMPDH2IMPDH1ARSLC22A12 | |
| SCHEMBL29489135 | 0.77 | IMPDH2 (0.64) | ALDH1A1IMPDH2IMPDH1ARSLC22A12 | |
| SCHEMBL2482764 | 0.76 | ALDH1A1 (0.53) | ALDH1A1ABCB11NR3C1CYP1A2CYP3A4 | |
| SCHEMBL1997655 | 0.75 | ALDH1A1 (0.75) | ALDH1A1ABCB11NR3C1CYP1A2CYP3A4 | |
| SCHEMBL11193357 | 0.75 | IMPDH2 (0.61) | ALDH1A1IMPDH2IMPDH1ARSLC22A12 | |
| SCHEMBL25484542 | 0.74 | ALDH1A1 (0.47) | ALDH1A1ABCB11NR3C1CYP1A2CYP3A4 | |
| SCHEMBL6392900 | 0.73 | CYP1A2 (0.55) | ALDH1A1ABCB11NR3C1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040963-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040963-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040963-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8344012-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344012-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344012-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8193234-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193234-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193234-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-102186827-A | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES INC | 2011-09-14 | — | — | CN | disclosed |
| US-20100056593-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056593-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056593-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056542-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056542-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056542-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040963-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | XDH, PON1, OAT | ALDH1A1 276/4885ABCB11 2439/4885NR3C1 2168/4885 |
| US-20100056593-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | ALDH1A1 276/4885ABCB11 2439/4885NR3C1 2168/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | ALDH1A1 587/4885ABCB11 1044/4885NR3C1 14/4885 |
| US-20100056542-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, OAT, PON1 | ALDH1A1 301/4885ABCB11 2152/4885NR3C1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.